Kyron.bio

Based in France, Kyron. bio is a biotechnology company specializing in advanced protein therapeutics through innovative glycan engineering, enhancing the efficacy and safety of antibody therapeutics for various medical applications. Kyron. bio, founded in 2022 in Paris, France, focuses on the development of advanced protein therapeutics utilizing glycan engineering.

The company has completed one deal and raised EUR 5. 5 million in Seed funding on May 12th, 2025, led by HCVC, with participation from Entrepreneur First, Saras Capital, and Verve Ventures. The founder's details are not publicly available. Kyron.

bio specializes in the development of advanced protein therapeutics through innovative glycan engineering. Their core offerings focus on the precise control of glycosylation patterns, enhancing the efficacy and safety of antibody therapeutics. The company serves pharmaceutical firms and research institutions aiming to improve therapeutic drug development, particularly in oncology and immunology, with operations primarily in France and Germany. Kyron.

bio generates revenue through strategic partnerships and collaborations with pharmaceutical companies, emphasizing the commercialization of their glycan engineering technologies. Revenue is typically derived from contractual agreements, including milestone payments and licensing fees. The company primarily engages in B2B transactions, allowing clients to enhance their drug development processes with Kyron. bio's proprietary technologies, thus facilitating a smooth transition from research to market readiness.

In May 2025, Kyron. bio raised EUR 5. 5 million in Seed funding to advance its glycan-engineering platform, grow its team, and conduct preclinical studies. The funding will support the development of upcoming products designed to meet specific therapeutic goals.

Additionally, Kyron. bio plans to expand into other European Union markets beyond France and Germany, leveraging their innovative capabilities to penetrate new regions by 2026.